A Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily SL Buprenorphine to Probuphine® Subdermal Implants

NCT02180659 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

177

Enrollment

INDUSTRY

Sponsor class

Conditions

Opioid Dependence

Interventions

DRUG: sublingual buprenorphine tablets
DRUG: Buprenorphine implant
DRUG: placebo implants
DRUG: sublingual placebo tablets

Sponsor

Titan Pharmaceuticals